Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
Chenyu Lin(Duke University), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Vanderson Rocha(Fundação Pró-Sangue Hemocentro de São Paulo), William Ying Khee Hwang(Singapore General Hospital), Olga Frankfurt, Patrick J. Stiff(Loyola University Medical Center), David Valcárcel(Vall d'Hebron Hospital Universitari), Daniela Cilloni(University of Turin), Corey Cutler(Harvard University), Gary J. Schiller(Fred Hutch Cancer Center), Mark C. Walters(UCSF Benioff Children's Hospital), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Claudio G. Brunstein(Hotel Dieu Hospital), Isabel Badell(Hospital de Sant Pau), Rabi Hanna(Cleveland Clinic), Joseph P. McGuirk(University of Kansas Medical Center), Caroline A. Lindemans(University Medical Center Utrecht), Ronit Simantov(Duke University), Guillermo Sanz(Instituto de Salud Carlos III), Ron Ram(Tel Aviv University), Amy K. Keating(Boston Children's Hospital), Nelson Hamerschlak(Hospital Israelita Albert Einstein), Joanne Kurtzberg(Duke University), Leonid Volodin(University of Virginia), Madan Jagasia(Vanderbilt University Medical Center), Andrew R. Rezvani(Stanford Blood Center), Liang Piu Koh(National University Cancer Institute, Singapore), Richard T. Maziarz(Oregon Health & Science University), Aurélie Schwarzbach(Gamida Cell (Israel)), Nicole Karras(City Of Hope National Medical Center), Suhag Parikh(Emory University), Juliana Folloni Fernandes(European Organisation for Rare Diseases), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k